| Recruiting | A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy) NCT06557460 | Regenerative Patch Technologies, LLC | Phase 2 |
| Not Yet Recruiting | A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration NCT07024732 | Eyevensys | Phase 1 |
| Not Yet Recruiting | Study to Detect Dendritic Cell Recruitment in Human Retina NCT06872658 | MindImmune Therapeutics, Inc. | — |
| Recruiting | Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Pla NCT06536062 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration NCT07428798 | Marmara University Pendik Training and Research Hospital | N/A |
| Not Yet Recruiting | Vision Improvement for Legally Blind Dry AMD Patients NCT04875234 | Optimal Acuity Corporation | — |
| Recruiting | Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study NCT06165068 | Navamindradhiraj University | Phase 3 |
| Active Not Recruiting | Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) NCT06229665 | LumiThera, Inc. | Phase 2 / Phase 3 |
| Recruiting | A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT) NCT06351605 | LumiThera, Inc. | — |
| Active Not Recruiting | Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study NCT05797896 | Complement Therapeutics | — |
| Recruiting | Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platele NCT05706896 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85 NCT05667688 | RBP4 Pty Ltd | Phase 1 |
| Completed | Hyperspectral Drusen Classification NCT06860555 | Optina Diagnostics Inc. | — |
| Completed | QA102 Phase II Study in Subjects With Dry AMD NCT05536752 | Smilebiotek Zhuhai Limited | Phase 2 |
| Not Yet Recruiting | Observation of the Natural Course of Age-related Macular Degeneration NCT05418231 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Completed | Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT) NCT05447650 | i-Lumen Scientific, Inc. | N/A |
| Recruiting | Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-relat NCT04627428 | Luxa Biotechnology, LLC | Phase 1 / Phase 2 |
| Withdrawn | Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) NCT04358471 | Hemera Biosciences | Phase 2 |
| Withdrawn | Microcurrent Stimulation for Dry Age-related Macular Degeneration NCT04511936 | i-Lumen Scientific, Inc. | N/A |
| Completed | CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration NCT04636853 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 3 |
| Terminated | HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 NCT04566445 | Gyroscope Therapeutics Limited | Phase 2 |
| Recruiting | Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic NCT04339764 | National Eye Institute (NEI) | Phase 1 / Phase 2 |
| Completed | Observational Study of Vision Improvement in Late Stage Dry AMD Patients NCT04349254 | Optimal Acuity Corporation | — |
| Terminated | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration NCT04643886 | Gemini Therapeutics, Inc. | Phase 2 |
| Completed | First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry NCT04246866 | Gemini Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) NCT04065490 | LumiThera, Inc. | N/A |
| Terminated | EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 NCT04437368 | Gyroscope Therapeutics Limited | Phase 2 |
| Completed | Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II) NCT03878420 | LumiThera, Inc. | N/A |
| Terminated | GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) NCT03894020 | Gyroscope Therapeutics Limited | — |
| Terminated | FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects NCT03846193 | Gyroscope Therapeutics Limited | Phase 1 / Phase 2 |
| Active Not Recruiting | PRIMA US-Feasibility Study in Atrophic Dry AMD NCT03392324 | Science Corporation | N/A |
| Unknown | Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Dis NCT02755428 | Chinese Academy of Sciences | Phase 1 / Phase 2 |
| Completed | Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular NCT03333954 | Science Corporation | N/A |
| Unknown | Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human E NCT03046407 | Chinese Academy of Sciences | Phase 1 / Phase 2 |
| Completed | A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A NCT03626636 | Allegro Ophthalmics, LLC | Phase 2 |
| Completed | Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 NCT03144999 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry NCT03305029 | CHA University | Phase 1 |
| Completed | Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration NCT02686658 | IVERIC bio, Inc. | Phase 2 / Phase 3 |
| Terminated | A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry A NCT01674829 | CHABiotech CO., Ltd | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With NCT01344993 | Astellas Institute for Regenerative Medicine | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macu NCT01379560 | Sucampo Pharma Americas, LLC | Phase 2 |
| Completed | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geograph NCT01002950 | Kubota Vision Inc. | Phase 2 |
| Completed | A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration NCT00950638 | Ophthotech Corporation | Phase 1 |
| Unknown | Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) t NCT00926861 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | — |
| Completed | Transcorneal Electrical Stimulation Therapy for Retinal Disease NCT00804102 | Okuvision GmbH | N/A |
| Suspended | Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration NCT00541333 | The New York Eye & Ear Infirmary | Phase 1 |
| Completed | Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degenerati NCT00429936 | Sirion Therapeutics, Inc. | Phase 2 |
| Completed | Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration. NCT00346060 | Radtke, Norman D., M.D. | Phase 2 |
| Completed | Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial NCT00751361 | Apheresis Research Institute | Phase 4 |